Savran Technologies develops non-invasive diagnostic tools that capture and analyze rare cells to detect diseases at early stages. This technology provides healthcare professionals with critical insights, enabling timely interventions that improve patient outcomes.
Funding
$7.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current diagnostic methods for diseases like cancer and complications in prenatal care often involve invasive procedures or lack the sensitivity to detect abnormalities at early stages. This can lead to delayed diagnoses and interventions, potentially impacting treatment outcomes and patient well-being.
Solution
Savran Technologies is developing a platform for non-invasive diagnostics through the capture and analysis of ultra-rare cells from blood samples. Their patented microfluidic technology enables high-efficiency isolation of circulating tumor cells (CTCs) for cancer diagnostics and circulating fetal cells for prenatal diagnostics. The platform offers a streamlined workflow, eliminating the need for a centrifuge in some applications, and provides high purity and single-cell capture capabilities. By providing access to intact genomes and enabling early detection, Savran Technologies aims to improve patient outcomes through timely and targeted interventions. The technology has been validated in clinical trials for triple-negative breast cancer and is being developed for various tumor types and prenatal applications, including preeclampsia screening.
Target Audience
The primary target audience includes researchers and clinicians in oncology and prenatal care, as well as diagnostic companies seeking to improve early disease detection and monitoring through non-invasive methods.
Features
- Patented microfluidic design for efficient capture of ultra-rare cells from blood
- High capture efficiency (90%+) and near-100% purity
- Streamlined workflow, operable with or without a centrifuge
- Gentle processing to maintain cell health for downstream analysis (fixed or live cells)
- Scalable for high-throughput applications
- Currently utilized in cancer diagnostics (CTC isolation for breast, lung, and pancreas cancers)
- Developing assays for prenatal diagnostics (fetal cell isolation and genetic analysis)